Experienced in Acrocephalopolydactyly

Simon Haefliger

Bern, BE, CH 
Experienced in Acrocephalopolydactyly
Bern, BE, CH 
OverviewLocationsClinical Research

Overview

Simon Haefliger practices in Bern, Switzerland. Mr. Haefliger is rated as an Experienced expert by MediFind in the treatment of Acrocephalopolydactyly. His top areas of expertise are Epithelioid Sarcoma, Fibrous Dysplasia, Fibromatosis, and Oral Cancer.

His clinical research consists of co-authoring 57 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Acrocephalopolydactyly.

Gender
Male

Locations

Bern, BE, Switzerland
Other Locations
Basel, BS, Switzerland
Lausanne, VD, Switzerland
Baden, AG, Switzerland
Kantonsspital Winterthur
Winterthur, ZH, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors: A Multicenter Open-label Single-arm Phase I Trial
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors: A Multicenter Open-label Single-arm Phase I Trial
Enrollment Status: Terminated
Publish Date: December 02, 2024
Intervention Type: Drug
Study Phase: Phase 1
Fibroblast Growth Factor Receptor (FGFR) Inhibitor Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) Overexpressing FGFR mRNA. A Multicenter, Single Arm Phase II Trial
Fibroblast Growth Factor Receptor (FGFR) Inhibitor Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) Overexpressing FGFR mRNA. A Multicenter, Single Arm Phase II Trial
Enrollment Status: Terminated
Publish Date: November 09, 2022
Intervention Type: Drug
Study Drug: Rogaratinib
Study Phase: Phase 2
View 1 Less Clinical Trial

57 Total Publications

Undifferentiated melanoma: a molecular study of a fatal metastatic "atypical fibroxanthoma (AFX)".
Undifferentiated melanoma: a molecular study of a fatal metastatic "atypical fibroxanthoma (AFX)".
Journal: Virchows Archiv : an international journal of pathology
Published: June 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Haefliger's expertise for a condition
ConditionClose
    View All 43 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile